%0 Journal Article
%T FDG-PET in Follicular Lymphoma Management
%A C. Bodet-Milin
%A T. Eug¨¨ne
%A T. Gastinne
%A E. Frampas
%A S. Le Gouill
%A F. Kraeber-Bod¨¦r¨¦
%J Journal of Oncology
%D 2012
%I Hindawi Publishing Corporation
%R 10.1155/2012/370272
%X 18-Fluoro-deoxyglucose positron emission tomography/computerised tomography (FDG PET/CT) is commonly used in the management of patients with lymphomas and is recommended for both initial staging and response assessment after treatment in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. Despite the FDG avidity of follicular lymphoma (FL), FDG PET/CT is not yet applied in standard clinical practice for patients with FL. However, FDG PET/CT is more accurate than conventional imaging for initial staging, often prompting significant management change, and allows noninvasive characterization to guide assessment of high-grade transformation. For restaging, FDG PET/CT assists in distinguishing between scar tissue and viable tumors in residual masses and a positive PET after induction treatment would seem to predict a shorter progression-free survival. 1. Introduction Follicular lymphoma (FL) is one of the most common types of lymphoma, representing around 25% of adult non-Hodgkin lymphomas (NHLs) worldwide [1]. FL evolution is highly variable with differences in clinical presentation, histological appearance, clinical behaviour, and response to therapy. Indeed, while some FL patients achieve prolonged complete remission (CR) other experience iterative relapses with or without histological transformation into a high-grade lymphoma (25¨C60%) [2, 3]. Treatment options, including watchful waiting, external radiotherapy, chemotherapy, monoclonal antibodies, radioimmunotherapy (RAIT), and biologic therapies, are guided by clinical features, the extent of disease at presentation and prognostic indices such as the FL international prognostic index (FLIPI) [4¨C6]. In order to segregate between patients with an indolent FL from those with more aggressive disease, risk stratification and identifying factors predictive of survival are of major interest in this disease. 18-Fluoro-deoxyglucose positron emission tomography (FDG PET/CT) is a noninvasive whole-body tri-dimensional imaging technique. FDG PET/CT is commonly used in the management of patients with lymphomas especially for initial staging and response assessment at the end of treatment in patients with diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL). Despite the now well recognized FDG avidity of FL, the use of FDG PET/CT is not recommended in standard practice [7¨C9]. Herein, we review using recent publications, the interest of FDG PET/CT in FL and the potential of new PET tracers such as radio-labeled monoclonal antibodies (MAbs). 2. FDG PET for Initial Staging In order to stage the
%U http://www.hindawi.com/journals/jo/2012/370272/